Argutus Medical Ltd. of Dublin, Ireland has named CeeTox Inc., Kalamazoo, MI, a preferred reference laboratory for the novel acute kidney injury (AKI) biomarker panel "the AKI Test®". In addition, CeeTox will also run Argutus' assays for kidney toxicity of the proximal tubule, distal tubule collecting duct and loop of Henle.

"Our AKI Test® panel of specific kidney injury assays lets pharmaceutical researchers and clinical trial directors know sooner whether drugs are causing renal damage. The AKI Test is composed of biomarker tests for proximal tubule, distal tubule and collecting duct injury, and thus identifies where in the kidney damage is occuring with much greater sensitivity and specificity than the traditional tests of creatinine or BUN," says Joe Keenan, Head of Sales & Marketing at Argutus. "By providing an earlier method of identifying potential adverse reactions, clinicians and researchers can modify their studies and treatment protocols, minimizing risk to patients and study participants, saving both time and money."

CeeTox has worked with kits from Argutus, formerly Biotrin, since its inception 6 years ago. According to Dr. James McKim, Founder and CSO of CeeTox, "Argutus kits are easy to use, cost effective and reliable. They are an integral part of our CTOX Panel offering.  We are pleased to be named a preferred reference laboratory by Argutus."

CeeTox is a leader in in vitro toxicity testing, with screens for  Acute Toxicity, Drug-Drug Interaction, Cardiotox, Skin Irritation, Skin Corrosion, Percutaneous Absorption, Phototoxicity, Ocular Corrosion and Irritation, Skin Sensitization, Endocrine Disruption, and In Vitro Acute OralTox LD50. 

For more information about the AKI Test® or site specific biomarkers, contact:
Joe Keenan
Head of Sales & Marketing at Argutus Medical
joe.keenan@argutusmed.com
ph. +353 1 670 8576 Ext. 201

Syed Ahmed Mustafa
Director of Sales & Marketing at CeeTox, Inc.
smustafa@ceetox.com
ph. +1 269-532-3800